Livivos
Livivos manufactures diagnostic medical equipment that employs advanced imaging techniques, such as elastography and MRI, to accurately detect liver diseases. This technology enables healthcare providers to deliver timely and effective treatment plans for patients suffering from liver conditions.
- Biotechnology
- Hardware
- Healthcare Technology
Funding
Raised to date
$300KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects millions, often progressing silently to more severe conditions like MASH and cirrhosis. Current diagnostic methods for liver steatosis can be slow, require specialized interpretation, and may not be readily accessible at the point of care. This lack of convenient and timely testing hinders early diagnosis, treatment qualification, and effective monitoring of therapeutic responses.
Solution
Livivos offers LiverScope®, a point-of-care device that utilizes patented MR-PDFF technology to quantify liver steatosis accurately and non-invasively. LiverScope® provides instant results without the need for image interpretation or histological examination, addressing the limitations of standard diagnostic modalities. This technology enables clinicians to identify patients who may benefit from emerging treatments, qualify patients for specific therapies (e.g., Resmetirom), and monitor treatment response through longitudinal PDFF testing. By providing rapid and accessible liver fat quantification, LiverScope® supports cost-effective disease management and improved patient outcomes.
Target Audience
The primary target audience includes hepatologists, clinical diagnostic experts, and pharmaceutical companies involved in clinical trials and post-market monitoring of liver disease treatments.
Features
- Point-of-care liver steatosis quantification using MR-PDFF technology
- Non-invasive measurement of liver fat, eliminating the need for biopsies
- Instant results without image interpretation, streamlining the diagnostic process
- Enables identification of patients with greater than 8% steatosis for targeted treatment
- Facilitates treatment qualification for drugs like Resmetirom
- Supports longitudinal monitoring of therapeutic response with >30% reduction in steatosis as a key indicator